|
(Health-NewsWire.Net, July 31, 2015 ) Hypercholesterolemia Pipeline Review H1 2015
RnRMarketResearch.com Adds “Hypercholesterolemia Pipeline Review H1 2015” which provides an overview of the Hypercholesterolemia therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H1, 2015 Pipeline Review of “Hypercholesterolemia” addition with 61 market data tables and 16 figures, spread across 216 pages is http://www.rnrmarketresearch.com/hypercholesterolemia-pipeline-review-h1-2015-market-report.html .
This report highlights examination al drugs from across over globe covering more than 20 treatment regions and around 3,000 proofs. The report is built using data and information sourced from our prohibitive databases, Company/University locales, SEC filings, money related authority presentations and highlighted press releases from association/school destinations and industry-specific outcast sources, set up together by our gathering. Pharmaceutical profiles/records highlighted in the report encounters incidental updation taking after a stringent course of action of methodology that ensures that each one of the profiles are upgraded with the latest plan of information. Also, techniques including live news & courses of action taking after, project based prepared box and clinical trials registries taking after insurance that the most recent enhancements are gotten on a nonstop start.
Companies Discussed/Mentioned in this Research:
Aegerion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., AtheroNova Inc., Bristol-Myers Squibb Company, Catabasis Pharmaceuticals, Inc., Cerenis Therapeutics Holding SA, CrystalGenomics, Inc., CymaBay Therapeutics, Inc., Daewon Pharm Co. Ltd., Dybly AG, Eli Lilly and Company, Esperion Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Hanmi Pharmaceuticals, Co. Ltd., Immune Response BioPharma, Inc., Johnson & Johnson, Kadmon Corporation, LLC, Kowa Company, Ltd., Merck & Co., Inc., Michigan Life Therapeutics, LLC, Novartis AG, Pfizer Inc., Planet Biotechnology Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Serometrix, LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Thetis Pharmaceuticals LLC, uniQure N.V. and Zhejiang Hisun Pharmaceutical Co., Ltd.
Drugs Profile Discussed in this Research :
(aspirin + lisinopril + lovastatin), (ezetimibe + atorvastatin calcium), AEM-28, AEM-28-02, AHRO-001, alipogene tiparvovec, alirocumab, ALN-PCSsc, AM-0010, anacetrapib, Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases, Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia, aplexone, bempedoic acid, BMS-962476, bococizumab, BSN-272, CAT-2003, CAT-2054, CER-001, Drugs to Inhibit Sortilin for Hypercholesterolemia, DW-3102, DYB-186, EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia, EP-80317, evacetrapib, evinacumab, evolocumab, fenofibrate, gemcabene calcium, Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia, Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia , HCP-1306, HS-25, IR-1002, J-17, KD-026, lomitapide mesylate, LY-3015014, MBX-8025, MGL-3196, mipomersen sodium, Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia, PCSK-9, PF-06678552, pitavastatin, pitavastatin CR, pradigastat sodium, Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia, Small Molecule to Inhibit PCSK9 for Hypercholesterolemia, Small Molecule to Inhibit PCSK9 for Hypercholesterolemia, Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders, Small Molecules to Inhibit PCSK9 for Hypercholesterolemia, Small Molecules to Inhibit PCSK9 for Hypercholesterolemia, SX-PCK9, Synthetic Peptide for Hypercholesterolemia, TP-452, VK-0214 and volanesorsen sodium
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=397266 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Therapeutics Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
